Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.

Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, Le H, Siebers N, Joas L, Morley R, Royer-Joo S, Pirzkall A, Salphati L, Ware JA, Morrissey KM.

Br J Clin Pharmacol. 2019 Aug;85(8):1751-1760. doi: 10.1111/bcp.13961. Epub 2019 Jun 14.

2.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
3.

Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.

Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D.

JAMA Ophthalmol. 2019 Jan 1;137(1):96-100. doi: 10.1001/jamaophthalmol.2018.5191.

PMID:
30383154
4.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

5.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J.

Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.

6.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

7.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

8.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

9.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O.

Oncogene. 2016 Dec 15;35(50):6403-6415. doi: 10.1038/onc.2016.170. Epub 2016 Jun 6.

10.

Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.

Fredrickson J, Serkova NJ, Wyatt SK, Carano RA, Pirzkall A, Rhee I, Rosen LS, Bessudo A, Weekes C, de Crespigny A.

Magn Reson Med. 2017 Feb;77(2):814-825. doi: 10.1002/mrm.26167. Epub 2016 Feb 26.

11.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

12.

Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, Hicks R, Wood K, Amler L, Fine BM, Loecke D, Pirzkall A.

Oncologist. 2014 Feb;19(2):175-6. doi: 10.1634/theoncologist.2013-0026. Epub 2014 Jan 23.

13.

High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC.

PLoS One. 2013;8(2):e56765. doi: 10.1371/journal.pone.0056765. Epub 2013 Feb 28. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/63f57c72-c869-4ef5-94d1-3cbd6c2e3678. AnDo [corrected to Do, An].

14.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

15.

Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Ozturk-Isik E, Pirzkall A, Lamborn KR, Cha S, Chang SM, Nelson SJ.

Transl Oncol. 2012 Feb;5(1):10-8. Epub 2012 Feb 1.

16.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

17.

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.

Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, Scott AM, Macfarlane D, Fine BM, Hicks RJ; OSI3926g Study Team.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):642-50. doi: 10.1007/s00259-010-1665-0. Epub 2011 Jan 5.

PMID:
21207024
18.

Molecular biomarker analyses using circulating tumor cells.

Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR.

PLoS One. 2010 Sep 8;5(9):e12517. doi: 10.1371/journal.pone.0012517.

19.

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ.

Neuro Oncol. 2010 Nov;12(11):1152-61. doi: 10.1093/neuonc/noq075. Epub 2010 Jul 20.

20.

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ.

Neuro Oncol. 2009 Dec;11(6):842-52. doi: 10.1215/15228517-2009-005.

21.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.

J Neurooncol. 2009 Feb;91(3):337-51. doi: 10.1007/s11060-008-9719-x. Epub 2008 Nov 15.

22.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.

J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3. Epub 2008 Sep 23.

23.

Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas.

Chuang CF, Chan AA, Larson D, Verhey LJ, McDermott M, Nelson SJ, Pirzkall A.

Technol Cancer Res Treat. 2007 Oct;6(5):375-82.

PMID:
17877425
24.

Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.

Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, Nelson SJ, Pirzkall A.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):381-9. Epub 2007 May 21.

25.

Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.

Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31.

PMID:
15850898
26.

Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.

Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, McDermott MW, Dillon WP, Nelson SJ.

J Neurosurg. 2004 Sep;101(3):467-75.

PMID:
15352605
27.

Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ.

J Magn Reson Imaging. 2004 May;19(5):546-54.

PMID:
15112303
28.

3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.

Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):126-37.

PMID:
15093908
29.

1H-MRSI of radiation effects in normal-appearing white matter: dose-dependence and impact on automated spectral classification.

Lee MC, Pirzkall A, McKnight TR, Nelson SJ.

J Magn Reson Imaging. 2004 Apr;19(4):379-88.

PMID:
15065160
30.

Portal venous and enteric exocrine drainage in simultaneous pancreas-kidney transplantation: experience with 70 consecutive transplant recipients.

Kortmann B, Pirzkall A, Pfeffer F, Hopt UT, Schareck WD.

Transplant Proc. 2003 Sep;35(6):2102-3. No abstract available.

PMID:
14529855
31.

Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients.

Herfarth KK, Izwekowa O, Thilmann C, Pirzkall A, Delorme S, Hofmann U, Schadendorf D, Zierhut D, Wannenmacher M, Debus J.

Strahlenther Onkol. 2003 Jun;179(6):366-71.

PMID:
12789461
32.

Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience.

Pirzkall A, Debus J, Haering P, Rhein B, Grosser KH, Höss A, Wannenmacher M.

Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72.

PMID:
12527049
33.

Comparison of intensity-modulated radiosurgery with gamma knife radiosurgery for challenging skull base lesions.

Nakamura JL, Pirzkall A, Carol MP, Xia P, Smith V, Wara WM, Petti PL, Verhey LJ, Sneed PK.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):99-109.

PMID:
12504041
34.

Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.

McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ.

J Neurosurg. 2002 Oct;97(4):794-802.

PMID:
12405365
35.

In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI.

Nelson SJ, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron DB, McKnight TR.

J Magn Reson Imaging. 2002 Oct;16(4):464-76. Review.

PMID:
12353260
36.

Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients.

Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ.

J Magn Reson Imaging. 2002 Sep;16(3):229-37.

PMID:
12205577
37.

Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy.

Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey LJ, Wara WW, Larson DA, Sneed PK.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1254-64.

PMID:
12128127
38.

The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets.

Pirzkall A, Carol MP, Pickett B, Xia P, Roach M 3rd, Verhey LJ.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):434-42.

PMID:
12023148
39.

Registration of magnetic resonance spectroscopic imaging to computed tomography for radiotherapy treatment planning.

Graves EE, Pirzkall A, Nelson SJ, Larson D, Verhey L.

Med Phys. 2001 Dec;28(12):2489-96.

PMID:
11797952
40.

High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.

Debus J, Wuendrich M, Pirzkall A, Hoess A, Schlegel W, Zuna I, Engenhart-Cabillic R, Wannenmacher M.

J Clin Oncol. 2001 Aug 1;19(15):3547-53.

PMID:
11481362
41.

MR-spectroscopy guided target delineation for high-grade gliomas.

Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson SJ, Verhey LJ, Larson DA.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28.

PMID:
11429219
42.

Adjuvant treatment of brain metastases.

Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J.

Semin Surg Oncol. 2001 Jan-Feb;20(1):50-6. Review.

PMID:
11291132
43.

Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors.

Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J.

Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80.

PMID:
11121636
44.

Conformal radiotherapy of challenging paraspinal tumors using a multiple arc segment technique.

Pirzkall A, Lohr F, Rhein B, Höss A, Schlegel W, Wannenmacher M, Debus J.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1197-204.

PMID:
11072179
45.

Conformal three-dimensional photon radiotherapy for paranasal sinus tumors.

Lohr F, Pirzkall A, Debus J, Rhein B, Höss A, Schlegel W, Wannenmacher M.

Radiother Oncol. 2000 Aug;56(2):227-31.

PMID:
10927142
46.

[First experiences with a noninvasive patient set-up system for radiotherapy of the prostate].

Herfarth KK, Pirzkall A, Lohr F, Schulz-Ertner D, Spoo J, Frank C, Bahner ML, Pastyr O, Debus J.

Strahlenther Onkol. 2000 May;176(5):217-22. German.

PMID:
10847118
47.

[Stereotactic one-time irradiation (radiosurgery). The methods, indications and results].

Debus J, Pirzkall A, Schlegel W, Wannenmacher M.

Strahlenther Onkol. 1999 Feb;175(2):47-56. Review. German.

PMID:
10065138
48.

Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases.

Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M.

J Clin Oncol. 1998 Nov;16(11):3563-9.

PMID:
9817276

Supplemental Content

Loading ...
Support Center